Àá½Ã¸¸ ±â´Ù·Á ÁÖ¼¼¿ä. ·ÎµùÁßÀÔ´Ï´Ù.
KMID : 1039620220120050361
Korean Journal of Family Practice
2022 Volume.12 No. 5 p.361 ~ p.366
The Efficacy of Using Liraglutide for Improving Non-Acoholic Fatty Liver Disease Condition in Pediatric-Adolescent Population with Obesity: Real World Evidence
Kim Min-Chul

Yum Keun-Sang
Abstract
Background: Nonalcoholic fatty liver disease (NAFLD) in the pediatric and adolescent population is known to contribute to the development of major outcomes such as liver cirrhosis and liver cancer later in life. Thus, the importance of determining the pathophysiology of and treating NAFLD has grown worldwide. However, definite guidelines are lacking. Liraglutide positively affects NAFLD through its various anti-obesity effects, including reducing the appetite by slowing the gastric emptying time and stimulating the central nervous system. Overall, liraglutide decreases visceral body fat, thus reducing inflammatory cytokines secreted by body fat and improving liver function. This study aimed to evaluate the feasibility of treating NAFLD patients with liraglutide.

Methods: This medical records analysis conducted between January and April 2022 included obese pediatric-adolescent patients who visited the family medicine department of a university hospital. Among them, only those with a serum glutamic oxaloacetic transaminase (SGOT)/serum glutamic pyruvic transaminase (SGPT) level ¡Ã40 IU/L were selected. Each was evaluated with serial blood tests, body composition analysis, and computed tomography to verify the feasibility of liraglutide to treat NAFLD.

Results: After treatment with liraglutide for >3 months, the research subjects¡¯ fasting glucose, SGOT, SGPT, and low-density lipoprotein cholesterol levels were significantly lowered versus baseline (P<0.05). Body composition indices including body mass index, waist-to-hip ratio, and percent body fat showed statistically significant changes (P=0.028, P=0.018, P=0.014, respectively). Moreover, visceral fat area improved after liraglutide use (P=0.043).

Conclusion: These findings suggest that liraglutide may treat obese pediatric and adolescent patients with NAFLD-induced abnormal liver function.
KEYWORD
Obesity, Nonalcoholic Fatty Liver Disease (NAFLD), Liraglutide, Child, Adolescent
FullTexts / Linksout information
Listed journal information
ÇмúÁøÈïÀç´Ü(KCI) ´ëÇÑÀÇÇÐȸ ȸ¿ø